In a mechanistic analysis of the SUMMIT trial that tested tirzepatide in patients with heart failure with preserved ejection fraction and obesity, treatment with this dual glucagon-like peptide-1 receptor and gastric inhibitory polypeptide agonist, as compared with placebo, reduced blood pressure and estimated circulatory volume–pressure overload, reduced systemic inflammation and mitigated cardiovascular and kidney injury.
- Barry A. Borlaug
- Michael R. Zile
- Milton Packer
